 CHICAGO--BUSINESS WIRE--Xeris Pharmaceuticals, Inc. Nasdaq: XERS, a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced the pricing of a registered direct offering of 6,553,398 shares of common stock, par value 0.0001 per share the Shares, to funds managed by Deerfield Management Company, L.P., which are existing investors in the Company, at a purchas 